Recombinant Factor VIIa Reduces Bleeding after Blunt Liver Injury in a Pig Model of Dilutional Coagulopathy under Severe Hypothermia

Background Recombinant factor VIIa (rFVIIa) is registered for use in haemophilia with inhibitors and other rare bleeding disorders, but has also been used in various other clinical conditions to terminate life-threatening bleeding. Underlying conditions (e.g. coagulopathy) and dosing may affect treatment efficacy. The objective of the present study was to evaluate the impact of increasing doses of rFVIIa on blood loss and coagulation assays in haemodiluted and hypothermic pigs undergoing blunt liver injury. Methods A grade III blunt liver injury was induced in 28 pigs after 70% haemodilution and cooling to 32.6–33.4°C. Ten minutes after trauma, animals randomly received placebo or 90, 180 or 360 μg/kg rFVIIa. Global coagulation parameters, thromboelastometry (TEM) and plasma thrombin generation (TG) were determined at different time points during the observation period of 120 minutes. Results Total blood loss was significantly lower following 90 μg/kg rFVIIa (1206 [1138–1470] mL) relative to placebo (2677 [2337–3068] mL; p<0.05), with no increased effect with higher dose levels of rFVIIa. Following trauma and haemodilution, coagulation was impaired relative to baseline in both TEM and TG analysis. At 60 and 120 minutes after trauma, TEM variables improved in the rFVIIa-treated animals compared with the placebo group. Similarly, rFVIIa improved coagulation kinetics in TG. As was observed with blood loss, no significant effect between different rFVIIa dose levels was found in TEM or TG. Macro- and microscopic post-mortem examination did not reveal any signs of thromboembolic events. Conclusion Early administration of 90 μg/kg rFVIIa reduced blood loss in pigs undergoing blunt liver injury even after severe haemodilution and hypothermia, with no further effect of higher dose levels. Coagulation assays showed impaired coagulation in coagulopathic animals, with a dose-independent improvement in animals treated with rFVIIa.

[1]  I. López-Vílchez,et al.  Impact of experimental haemodilution on platelet function, thrombin generation and clot firmness: effects of different coagulation factor concentrates. , 2013, Blood transfusion = Trasfusione del sangue.

[2]  J. Vincent,et al.  Management of bleeding and coagulopathy following major trauma: an updated European guideline , 2013, Critical Care.

[3]  O. Grottke.  Coagulation management , 2012, Current opinion in critical care.

[4]  R. van Oerle,et al.  Preanalytic variables of thrombin generation: towards a standard procedure and validation of the method , 2012, Journal of thrombosis and haemostasis : JTH.

[5]  R. Rossaint,et al.  Thrombin Generation Capacity of Prothrombin Complex Concentrate in an In Vitro Dilutional Model , 2012, PloS one.

[6]  K. Brohi,et al.  Acute traumatic coagulopathy , 2012, Current opinion in anaesthesiology.

[7]  M. Dubick,et al.  Effects of In vitro hemodilution, hypothermia and rFVIIa addition on coagulation in human blood. , 2012, International journal of burns and trauma.

[8]  J. Reifman,et al.  Kinetic modeling sheds light on the mode of action of recombinant factor VIIa on thrombin generation. , 2011, Thrombosis research.

[9]  R. Rossaint,et al.  Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury. , 2011, Blood.

[10]  O. Olsen,et al.  Tissue factor and factor VIIa cross-species compatibility. , 2011, Frontiers in bioscience.

[11]  K. Hansson,et al.  Prothrombin complex concentrate and recombinant prothrombin alone or in combination with recombinant factor X and FVIIa in dilutional coagulopathy: a porcine model , 2011, Journal of thrombosis and haemostasis : JTH.

[12]  R. Rossaint,et al.  Recombinant factor VIIa reduces bleeding after blunt liver injury in coagulopathic, hypofibrinogenaemic pigs. , 2010, British journal of anaesthesia.

[13]  G. Bernard,et al.  Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage. , 2010, The Journal of trauma.

[14]  R. Rossaint,et al.  Effects of different fibrinogen concentrations on blood loss and coagulation parameters in a pig model of coagulopathy with blunt liver injury , 2010, Critical care.

[15]  W. Voelckel,et al.  Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM®)-guided administration of fibrinogen concentrate and prothrombin complex concentrate , 2010, Critical care.

[16]  R. Rossaint,et al.  A New Model for Blunt Liver Injuries in the Swine , 2009, European Surgical Research.

[17]  J. Ingerslev,et al.  Mechanisms of hydroxyethyl starch‐induced dilutional coagulopathy , 2009, Journal of thrombosis and haemostasis : JTH.

[18]  Kevin Mackway-Jones,et al.  The coagulopathy of trauma: a review of mechanisms. , 2008, The Journal of trauma.

[19]  M. Dubick,et al.  Thrombelastography is better than PT, aPTT, and activated clotting time in detecting clinically relevant clotting abnormalities after hypothermia, hemorrhagic shock and resuscitation in pigs. , 2008, The Journal of trauma.

[20]  A. Pusateri,et al.  Effect of haemodilution, acidosis, and hypothermia on the activity of recombinant factor VIIa (NovoSeven®) , 2008, British journal of anaesthesia.

[21]  C. Wade,et al.  The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. , 2008, The Journal of trauma.

[22]  M. Cohen,et al.  Acute coagulopathy of trauma: mechanism, identification and effect , 2007, Current opinion in critical care.

[23]  J. Holcomb,et al.  RECOMBINANT FACTOR VIIA REDUCES REBLEED HEMORRHAGE VOLUME IN A SWINE AORTOTOMY MODEL: A RANDOMIZED DOUBLE-BLINDED STUDY , 2007, Shock.

[24]  J. Holcomb,et al.  In vivo bleeding time and in vitro thrombelastography measurements are better indicators of dilutional hypothermic coagulopathy than prothrombin time. , 2007, The Journal of trauma.

[25]  D. Howes,et al.  Administration of recombinant factor VIIa decreases blood loss after blunt trauma in noncoagulopathic pigs. , 2007, The Journal of trauma.

[26]  U. Hedner.  Mechanism of action of factor VIIa in the treatment of coagulopathies. , 2006, Seminars in thrombosis and hemostasis.

[27]  K. Ryan,et al.  Effect of recombinant FVIIa in hypothermic, coagulopathic pigs with liver injuries. , 2005, The Journal of trauma.

[28]  R. Seitz,et al.  Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[29]  Alisa S Wolberg,et al.  The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. , 2003, The Journal of trauma.

[30]  Mauricio Lynn,et al.  Early coagulopathy predicts mortality in trauma. , 2003, The Journal of trauma.

[31]  J. Macleod,et al.  Early injection of high-dose recombinant factor VIIa decreases blood loss and prolongs time from injury to death in experimental liver injury. , 2002, Journal of Trauma.

[32]  J. Holcomb,et al.  The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries. , 2002, The Journal of trauma.

[33]  U. Hedner.  Treatment of Patients with Factor VIII and Factor IX Inhibitors with Special Focus on the Use of Recombinant Factor VIIa , 1999, Thrombosis and Haemostasis.

[34]  J. Oliver,et al.  Platelet activity of high‐dose factor VIIa is independent of tissue factor , 1997, British journal of haematology.

[35]  R. Bertina,et al.  The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. , 1990, The Biochemical journal.